BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32068651)

  • 21. Acute megakaryoblastic leukemia in Down syndrome: orbital infiltration.
    Olson JL; May MJ; Stork L; Kadan N; Bateman JB
    Am J Ophthalmol; 2000 Jul; 130(1):128-30. PubMed ID: 11004278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient abnormal myelopoiesis in neonates: GATA get the diagnosis.
    Bombery M; Vergilio JA
    Arch Pathol Lab Med; 2014 Oct; 138(10):1302-6. PubMed ID: 25268193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute megakaryoblastic leukemia. Relation to trisomy 21].
    Levaltier X; Reman O; Boutard P; Mandard JC; Troussard X; Leporrier M
    Arch Fr Pediatr; 1991 Oct; 48(8):563-6. PubMed ID: 1837448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. t(5;7)(q34;q21) in acute megakaryoblastic leukemia associated with Down syndrome.
    Ma SK; Ha SY; Wan TS; Chan LC
    Cancer Genet Cytogenet; 1997 Jul; 96(2):177. PubMed ID: 9216727
    [No Abstract]   [Full Text] [Related]  

  • 26. Megakaryoblastic disorders in children.
    Lorsbach RB
    Am J Clin Pathol; 2004 Dec; 122 Suppl():S33-46. PubMed ID: 15690641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A t(1;22)(p13;q13) in four children with acute megakaryoblastic leukemia (M7), two with Down syndrome.
    Trejo RM; Aguilera RP; Nieto S; Kofman S
    Cancer Genet Cytogenet; 2000 Jul; 120(2):160-2. PubMed ID: 10942809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome.
    Vial Y; Lachenaud J; Verloes A; Besnard M; Fenneteau O; Lainey E; Marceau-Renaut A; Preudhomme C; Baruchel A; Cavé H; Drunat S
    Haematologica; 2018 Jun; 103(6):e274-e276. PubMed ID: 29217785
    [No Abstract]   [Full Text] [Related]  

  • 30. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 31. Interphase cytogenetic analysis of clonality in peripheral blood cells from a patient with Down syndrome and acute megakaryoblastic leukemia.
    Chang H; Li D; Nayar R; Ye C; Lau W; Sutherland DR
    Cancer Genet Cytogenet; 2004 Jan; 148(2):141-4. PubMed ID: 14734226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eyelid mass as the presenting finding in a child with Down syndrome and acute megakaryoblastic leukemia.
    Sandoval C; Davis A; Jayabose S
    Pediatrics; 2005 Mar; 115(3):810-1. PubMed ID: 15741393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J; Zipursky A
    Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract]   [Full Text] [Related]  

  • 34. Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome.
    Hirose Y; Kudo K; Kiyoi H; Hayashi Y; Naoe T; Kojima S
    Leukemia; 2003 Nov; 17(11):2250-2. PubMed ID: 12931214
    [No Abstract]   [Full Text] [Related]  

  • 35. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute myeloblastic leukemia 5q-. Clinical and cytogenetic remission by means of intensive chemotherapy].
    Las Heras G; Ribera JM; Granada I; Millá F
    Sangre (Barc); 1991 Jun; 36(3):251-2. PubMed ID: 1948550
    [No Abstract]   [Full Text] [Related]  

  • 37. Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia.
    De Marchi F; Araki M; Komatsu N
    Expert Rev Hematol; 2019 May; 12(5):285-293. PubMed ID: 30991862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
    Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
    Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective analysis of gene fusions and treatment outcomes in pediatric acute megakaryoblastic leukemia without Down syndrome.
    Suzuki K; Hama A; Okuno Y; Xu Y; Narita A; Yoshida N; Muramatsu H; Nishio N; Kato K; Kojima S; Yoo KH; Takahashi Y
    Haematologica; 2024 Jun; 109(6):1936-1940. PubMed ID: 38299674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.